Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

34.52 +0.07 (+0.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exelixis Inc

< Previous 1 2 3 4 5 Next >
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
From Exelixis, Inc.
Via Business Wire
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
3 Stocks to Buy for a Soft Landing, If There Is One
Recent economic data is reigniting talk about a soft landing for the economy; here are three stocks to consider if a soft landing materializes 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
From Exelixis, Inc.
Via Business Wire
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
From FN Media Group LLC
Via GlobeNewswire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
From Exelixis, Inc.
Via Business Wire
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
From Exelixis, Inc.
Via Business Wire
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
From Exelixis, Inc.
Via Business Wire
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
From Exelixis, Inc.
Via Business Wire
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.